About Abl interactor 1
Abl interactor 1 (ABI1) is a protein
from Homo sapiens identified by UniProt accession
Q8IZP0, 508 residues long.
MolForge cross-references it against 0 known binders and
170 disease associations.
Target properties
| Protein name | Abl interactor 1 |
| UniProt accession | Q8IZP0 |
| Gene | ABI1 |
| Organism | Homo sapiens |
| Length | 508 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (170)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- lobular breast carcinoma · score 0.37
- kidney neoplasm · score 0.37
- lymphoid neoplasm · score 0.37
- breast ductal adenocarcinoma · score 0.37
- prostate adenocarcinoma · score 0.37
- bile duct carcinoma · score 0.37
- esophageal adenocarcinoma · score 0.37
- Hepatobiliary Neoplasm · score 0.37
- HER2 Positive Breast Carcinoma · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8IZP0-F1 | alphafold | PREDICTED | 65.34 | — |
Amino-acid sequence (508 residues)
MAELQMLLEE EIPSGKRALI ESYQNLTRVA DYCENNYIQA TDKRKALEET KAYTTQSLAS VAYQINALAN NVLQLLDIQA SQLRRMESSI NHISQTVDIH KEKVARREIG ILTTNKNTSR THKIIAPANM ERPVRYIRKP IDYTVLDDVG HGVKWLKAKH GNNQPARTGT LSRTNPPTQK PPSPPMSGRG TLGRNTPYKT LEPVKPPTVP NDYMTSPARL GSQHSPGRTA SLNQRPRTHS GSSGGSGSRE NSGSSSIGIP IAVPTPSPPT IGPENISVPP PSGAPPAPPL APLLPVSTVI AAPGSAPGSQ YGTMTRQISR HNSTTSSTSS GGYRRTPSVT AQFSAQPHVN GGPLYSQNSI SIAPPPPPMP QLTPQIPLTG FVARVQENIA DSPTPPPPPP PDDIPMFDDS PPPPPPPPVD YEDEEAAVVQ YNDPYADGDP AWAPKNYIEK VVAIYDYTKD KDDELSFMEG AIIYVIKKND DGWYEGVCNR VTGLFPGNYV ESIMHYTD
Explore Abl interactor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets